CPT code 81223 identifies comprehensive sequencing of the full cystic fibrosis transmembrane conductance regulator gene (CFTR). Nationally, this code represents an advanced genetic diagnostic service used to identify pathogenic sequence variants that cause cystic fibrosis or related disorders. Full-gene CFTR sequencing is clinically important for diagnostic confirmation, carrier screening in select contexts, and guiding genetic counseling and care planning.

Key payers included in the discussion are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how CPT code 81223 is covered across major payers, common billing modifiers in use, and typical sites where the test is performed.

Readers will learn practical details about the clinical context for ordering full CFTR sequencing, typical laboratory service settings, and which payers commonly reimburse or apply specific coverage policies. The report also summarizes benchmark considerations for utilization and notes where payer policy language commonly addresses medical necessity, prior authorization, or testing hierarchy (for example, when targeted mutation panels are considered before full sequencing). Data not available in the input is clearly identified where applicable.